Overactive Bladder, Pharmacokinetics
Conditions
Keywords
YM178, Mirabegron, DDI, Phase I, Warfarin, Pharmacokinetics
Brief summary
This study investigates whether YM178 has an effect on the pharmacokinetics of warfarin, to exclude any drug-drug interaction between YM178 and warfarin, and evaluates the safety and tolerability of warfarin alone and combined with YM178.
Interventions
DRUGwarfarin
Oral
DRUGYM178
Oral
Sponsors
Astellas Pharma Inc
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Female subject must be of non-child bearing potential, i.e. postmenopausal, surgically sterilized (e.g. tubal ligation), hysterectomy in medical history, or must practice adequate (double barrier) non-hormonal contraceptive methods to prevent pregnancies. * Body Mass Index (BMI) ≥ 18.5 and \< 30 kg/m2, inclusive
Exclusion criteria
* Female who is pregnant * Any of the liver function tests (i.e. alanine aminotransferase (ALT), aspartate aminotransferase (AST) and Alkaline Phosphatase (AP)) above the upper limit of normal (ULN) * Any clinically significant history of disease or disorder - gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological, dermatological, psychiatric or metabolic as judged by the medical investigator * Abnormal pulse and/or blood pressure measurements and the pre-study as follows: Pulse \< 40 or \> 90 bpm; mean systolic blood pressure \> 140 mmHg; mean diastolic blood pressure \> 90 mmHg (blood measurements taken in triplicate after subject has been resting in supine position for 5 min; pulse will be measured automatically * A marked baseline prolongation of QT/QTc interval after repeated measurements of \>450 ms, a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS) * Use of any prescribed or OTC (over-the counter) drugs (including vitamins, natural and herbal remedies, e.g. St. John's wort) in the 2 weeks prior to admission to the Clinical Unit, except for paracetamol (up to 3 g/day) * Any use of drugs of abuse within 3 months prior to admission to the clinical unit * History of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the clinical unit * History of drinking more than 21 units of alcohol per week (1 unit = 270 ml of beer or 40 ml of spirits or 1 glass of wine) (\> 14 units of alcohol for female subjects) within 3 months prior to admission to the clinical unit * Donation of blood or blood products within 3 months prior to admission to the clinical unit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| R- and S-warfarin in plasma: AUCinf, AUClast, Cmax, tmax, t1/2, CL/F | Day 1-9 and 15-31 |
| The AUCinf of both enantiomers will be used to assess the potential drug-drug interaction. | Day 1/2 and 15/16 |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events, clinical laboratory tests (hematology, biochemistry, urinalysis), vital signs, 12-lead ECG, physical examination | Day -1 - 31 |
| YM178 in plasma: Ctrough, AUCtau, Cmax, tmax, CL/F | Day 20-24 |
| Degree of anticoagulation: AUCPT;0-168h (area under the prothrombin time versus time curve from 0 to 168 h after dosing with warfarin), AUCINR;0-168h, maximum PT (PTmax), time to reach PTmax (tPT; max), INRmax, tINR;max | Day 1-9 and 23-31 |
Countries
France
Outcome results
None listed